A randomized, open, multicenter phase II study of efficacy and safety comparing XELOX and a PD-1 inhibitor and a bevacizumab biosimilar drug (DAITON)with XELOX and a bevacizumab biosimilar drug (DAITON)in the first-line treatment of RAS mutated pMMR /MSS advanced colorectal cancer patients
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2717045
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: group A :XELOX combined with PD-1 inhibitor and bevacizumab biosimilar;group B :XELOX in combination with bevacizumab biosimilar
Primary outcome(s): l Progression-free survival (PFS) was compared and assessed according to RECIST1.1 and IRRECIST
Study Design: Parallel
创建时间：
2021-07-15
